Risk factors for invasive aspergillosis in ICU patients with COVID-19: current insights and new key elements.
Acute respiratory distress syndrome
CAPA
COVID-19
COVID-19-associated pulmonary aspergillosis
Invasive pulmonary aspergillosis
SARS-CoV-2
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
15 Sep 2021
15 Sep 2021
Historique:
received:
26
06
2021
accepted:
29
08
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
16
9
2021
Statut:
epublish
Résumé
Invasive pulmonary aspergillosis (IPA) has always been a challenging diagnosis and risk factors an important guide to investigate specific population, especially in Intensive Care Unit. Traditionally recognized risk factors for IPA have been haematological diseases or condition associated with severe immunosuppression, lately completed by chronic conditions (such as obstructive pulmonary disease, liver cirrhosis, chronic kidney disease and diabetes), influenza infection and Intensive Care Unit (ICU) admission. Recently, a new association with SARS-CoV2 infection, named COVID-19-associated pulmonary aspergillosis (CAPA), has been reported worldwide, even if its basic epidemiological characteristics have not been completely established yet. In this narrative review, we aimed to explore the potential risk factors for the development of CAPA and to evaluate whether previous host factors or therapeutic approaches used in the treatment of COVID-19 critically ill patients (such as mechanical ventilation, intensive care management, corticosteroids, broad-spectrum antibiotics, immunomodulatory agents) may impact this new diagnostic category. Reviewing all English-language articles published from December 2019 to December 2020, we identified 21 papers describing risk factors, concerning host comorbidities, ICU management, and COVID-19 therapies. Although limited by the quality of the available literature, data seem to confirm the role of previous host risk factors, especially respiratory diseases. However, the attention is shifting from patients' related risk factors to factors characterizing the hospital and intensive care course, deeply influenced by specific features of COVID treatment itself. Prolonged invasive or non-invasive respiratory support, as well as the impact of corticosteroids and/or immunobiological therapies seem to play a pivotal role. ICU setting related factors, such as environmental factors, isolation conditions, ventilation systems, building renovation works, and temporal spread with respect to pandemic waves, need to be considered. Large, prospective studies based on new risk factors specific for CAPA are warranted to guide surveillance and decision of when and how to treat this particular population.
Identifiants
pubmed: 34524562
doi: 10.1186/s13613-021-00923-4
pii: 10.1186/s13613-021-00923-4
pmc: PMC8441237
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
136Informations de copyright
© 2021. The Author(s).
Références
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
Am J Respir Crit Care Med. 2020 Jul 1;202(1):132-135
pubmed: 32396381
Mycoses. 2020 Dec;63(12):1368-1372
pubmed: 32965042
Clin Infect Dis. 2020 Aug 14;71(4):1106-1119
pubmed: 31900476
IDCases. 2020;22:e00935
pubmed: 32864340
Med Mycol Case Rep. 2021 Mar;31:2-5
pubmed: 32395423
Mycoses. 2020 Aug 4;:
pubmed: 32749040
Mycoses. 2021 Feb;64(2):132-143
pubmed: 33210776
Clin Infect Dis. 2020 Aug 29;:
pubmed: 32860682
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Am J Respir Crit Care Med. 2020 Oct 15;202(8):1071-1073
pubmed: 32730104
J Fungi (Basel). 2020 Jun 24;6(2):
pubmed: 32599813
Am J Respir Crit Care Med. 2012 Jul 1;186(1):56-64
pubmed: 22517788
Mycoses. 2020 Aug;63(8):766-770
pubmed: 32585069
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Am J Respir Crit Care Med. 2020 Jul 15;:
pubmed: 32668167
Crit Care. 2020 Jun 16;24(1):353
pubmed: 32546188
Lancet Respir Med. 2020 Jun;8(6):e48-e49
pubmed: 32445626
J Fungi (Basel). 2020 Jul 10;6(3):
pubmed: 32664423
Med Mycol. 2011 Apr;49 Suppl 1:S7-S12
pubmed: 20718606
Eur J Clin Invest. 2020 Oct;50(10):e13319
pubmed: 32535894
Ann Intensive Care. 2020 Jun 1;10(1):71
pubmed: 32488446
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Diagnostics (Basel). 2020 Oct 10;10(10):
pubmed: 33050499
Crit Care. 2020 Sep 1;24(1):538
pubmed: 32867810
J Microbiol Immunol Infect. 2021 Feb;54(1):46-53
pubmed: 33012653
Med Mycol. 2021 Jan 4;59(1):110-114
pubmed: 32914189
Intensive Care Med. 2012 Nov;38(11):1761-8
pubmed: 22895826
Front Cell Infect Microbiol. 2021 Feb 26;11:624483
pubmed: 33718270
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Crit Care. 2020 Jun 5;24(1):299
pubmed: 32503617
Ann Ist Super Sanita. 2020 Jul-Sep;56(3):359-364
pubmed: 32959802
Clin Microbiol Infect. 2020 Dec;26(12):1706-1708
pubmed: 32659385
J Infect Dis. 2021 Mar 26;:
pubmed: 33770176
Open Forum Infect Dis. 2021 Feb 04;8(3):ofab065
pubmed: 33732753
J Crit Care. 2020 Oct;59:149-155
pubmed: 32674001
Am J Respir Crit Care Med. 2020 Sep 15;202(6):902-903
pubmed: 32687389
Intensive Care Med. 2020 Aug;46(8):1524-1535
pubmed: 32572532
Clin Infect Dis. 2007 Jul 15;45(2):205-16
pubmed: 17578780
Lancet Respir Med. 2018 Oct;6(10):782-792
pubmed: 30076119
Crit Care. 2015 Jan 12;19:7
pubmed: 25928694
Clin Microbiol Infect. 2021 Jan;27(1):147-148
pubmed: 32768493
Eur J Clin Microbiol Infect Dis. 2021 Apr;40(4):859-869
pubmed: 33140176
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33084566
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
Curr Hypertens Rep. 2020 Jun 13;22(6):43
pubmed: 32535705
Clin Infect Dis. 2020 Jul 28;:
pubmed: 32719848
J Fungi (Basel). 2021 May 15;7(5):
pubmed: 34063556